Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

2.76
-0.02 (-0.54%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :188,979
Date :09-24-2020

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting

September 21st, 2020|Comments Off on Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting

Oral Presentation on Oral Insulin Effect on Diabetes and Poster Presentation on Oral Insulin Effect on NASH NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical [...]

Oramed’s Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients

September 15th, 2020|Comments Off on Oramed’s Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients

91% of T1D patients and 85% of T2D patients surveyed indicated they were "extremely likely" or "very likely" to ask their doctors about ORMD-0801 NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: [...]

Oramed to Present at H.C. Wainwright Global Investment Conference

September 3rd, 2020|Comments Off on Oramed to Present at H.C. Wainwright Global Investment Conference

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present [...]

Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin

July 15th, 2020|Comments Off on Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin

NEW YORK, July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive [...]